
ABOUT US
InspiroGeneTM by McKesson (“InspiroGene”) is a dedicated business focused solely on supporting the commercialization of cell and gene therapies (CGTs). With a scalable, flexible suite of services and an experienced leadership team, InspiroGene enables manufacturers, payers, and providers to navigate the complex CGT commercialization landscape to ensure patients can access the life-changing treatments they need.
InspiroGene brings unparalleled experience in every stage of the CGT life cycle and has established the following solutions to address the complex challenges of bringing CGTs to market:
- Third-party logistics (3PL) programs that meet the unique demands of CGT manufacturers, with financial management solutions, logistics, and cutting-edge data analytics to provide seamless operations for CGTs.
- Specialty distribution services that leverage McKesson’s extensive supply chain network, offering high-touch logistics and advanced data analytics to ensure CGTs reach patients efficiently and effectively.
- Specialty pharmacy solutions dedicated to CGTs, including precision dispensing to expedite time to treatment, and patient management services to efficiently address the unique needs of patients based on therapy type.
- CGT dedicated patient hub that provides tailored access and support services for patients, as well as operational case management for providers, patients, and caregivers.
In addition, InspiroGene offers a technology platform that provides visibility within the CGT value chain by integrating product data and financial flows to empower CGT manufacturers, providers, and patients to deliver exceptional care and achieve transformative clinical outcomes.
FEATURED VIDEOS

What Does InspiroGene Bring To The CGT Space And To The Patients It Serves?
Joe DePinto, Head of Cell Gene and Advanced Therapies at McKesson, discusses what InspiroGene brings to the cell and gene therapy (CGT) space and the patients it serves.
CONTACT INFORMATION
InspiroGene
6555 State Hwy 161
Irving, TX 75039
UNITED STATES
Contact: Carson Rhodes
FEATURED INSIGHTS
-
Learn why enabling community hospitals to alleviate system constraints would usher a change in the future of cell and gene therapy delivery.
-
The patient, product, and value chains for cell and gene therapies are far different than traditional healthcare delivery and requires new and specialized sets of capabilities at hospitals.
-
Delve into this exploration of the challenges and opportunities facing CGTs, including manufacturing, supply chain logistics, and the need for greater collaboration among stakeholders.
-
Explore the findings of a survey of 124 U.S. oncologists focused on better understanding the current use of cell and gene therapies (CGTs) and possible barriers to future adoption.
FEATURED SOLUTIONS
-
Learn about the range of services provided by InspiroGene By McKesson and the company’s unique points of difference as a commercial ally to stakeholders in the CGT industry.